Axe Compute Inc (AGPU) AI Stock Analysis

• Market Cap: $23.16M
• Dividend Yield: N/A
• Average Volume (3M): 173.82K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.79
• Revenue Growth: -47.20%
• EPS Growth: -163.70%
• Country: US
• Employees: 23
• Sector: Healthcare
• Sector Strength: 45
• Industry: Software - Infrastructure
• EPS (TTM): -107.25
• Shares Outstanding: 3,393,516
• 10 Day Avg. Volume: 72,596
• 30 Day Avg. Volume: 173,821
• PEG Ratio: 0.15
• Price to Book (P/B): -331.08
• Price to Sales (P/S): 41.31
• P/FCF Ratio: -5.61
• Enterprise Value/Market Cap: 0.51
• Enterprise Value/Revenue: 16.23
• Enterprise Value/Gross Profit: 32.30
• Enterprise Value/Ebitda: -0.14
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $6.50 ▼(-9.72% Downside)

The score is primarily dragged down by very weak financial performance—materially declining revenue, outsized losses, ongoing cash burn, and deeply negative equity. Technicals are only neutral (some short-term stabilization but still below longer-term averages), while valuation is constrained by negative earnings and no provided dividend yield.

Positive Factors

Strategic Alliances

Strategic alliances expand the application of predictive analytics in cancer treatment, potentially increasing revenue through broader market reach.

Proprietary Platform

The proprietary platform provides a competitive edge by offering unique solutions for personalized cancer treatment, fostering long-term client relationships.

Research Collaborations

Collaborations with pharmaceutical companies and research institutions enhance innovation and provide steady revenue streams, supporting sustainable growth.

Negative Factors

Declining Revenue

A significant decline in revenue growth indicates challenges in maintaining market share and could impact the company's ability to invest in future growth.

Negative Cash Flow

Persistent negative cash flow highlights liquidity issues, limiting the company's ability to fund operations and invest in growth opportunities.

Solvency Risk

Negative equity suggests a weak capital structure, posing risks to financial stability and potentially hindering the company's ability to secure financing.

Axe Compute Inc Business Overview & Revenue Model

Company Description

Axe Compute Inc., a knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of cancer therapies. It operates through two segments, Pittsburgh and Eagan. The Pittsburgh segment provides services that include the application of AI using its proprietary biobank of 150,000+ tumor samples. This segment also creates proprietary 3D culture models used in drug development. Its Eagan segment produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. Predictive Oncology Inc. has a strategic collaboration with Every Cure to identify and prioritize drugs for repurposing. The company was formerly known as Predictive Oncology Inc. and changed its name to Axe Compute Inc. in December 2025. Axe Compute Inc. was incorporated in 2002 and is headquartered in Pittsburgh, Pennsylvania.

How the Company Makes Money

Predictive Oncology generates revenue through a combination of research collaborations, licensing agreements, and direct service offerings. Key revenue streams include partnerships with pharmaceutical companies and research institutions that utilize POAI's technology for drug development and clinical trials. The company also earns income by providing laboratory services for analyzing tumor samples and conducting predictive modeling. Additionally, strategic alliances with healthcare providers and participation in industry consortia further enhance its revenue potential by expanding the application of its predictive analytics in cancer treatment.

Axe Compute Inc Financial Statement Overview

Summary

The company faces significant financial challenges with declining revenues, negative profit margins, and deteriorating liquidity and solvency metrics. The balance sheet reveals financial instability with negative stockholders' equity, indicating potential solvency issues.

Income Statement

The company shows a declining revenue trend with a negative revenue growth rate over the years. Gross profit margin has decreased from 64.7% in 2023 to 49.1% in 2024. The net profit margin is severely low due to net losses. EBIT and EBITDA margins are negative, indicating operational inefficiencies.

Balance Sheet

The balance sheet reveals financial instability with a negative stockholders' equity in 2024, indicating potential solvency issues. Debt-to-equity ratio is not applicable due to negative equity. The equity ratio is negative, reflecting a concerning capital structure.

Cash Flow

Operating cash flows remain negative, highlighting ongoing liquidity challenges. Free cash flow is also negative, but there is a slight improvement in free cash flow growth rate from 2023 to 2024. The operating cash flow to net income ratio is negative, indicating inefficiencies in converting income to cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	728.20K	1.62M	1.63M	1.51M	1.42M	1.25M
Gross Profit	365.87K	797.68K	1.02M	1.00M	933.66K	805.08K
EBITDA	-83.09M	-10.24M	-11.87M	-13.95M	-12.13M	-11.46M
Net Income	-84.33M	-12.20M	-13.98M	-25.74M	-19.66M	-25.88M
Balance Sheet
Total Assets	3.14M	4.97M	14.42M	25.73M	43.77M	13.06M
Cash, Cash Equivalents and Short-Term Investments	181.67K	734.67K	8.73M	22.07M	28.20M	678.33K
Total Debt	1.89M	2.13M	2.73M	180.32K	879.33K	5.87M
Total Liabilities	80.57M	5.18M	6.15M	3.97M	3.51M	10.42M
Stockholders Equity	-77.43M	-202.61K	8.27M	21.77M	40.27M	2.64M
Cash Flow
Free Cash Flow	-8.78M	-11.97M	-13.21M	-12.85M	-13.17M	-12.62M
Operating Cash Flow	-8.78M	-11.96M	-13.19M	-12.37M	-12.21M	-12.26M
Investing Cash Flow	657.00K	22.49K	-302.37K	-475.70K	-10.61M	-167.46K
Financing Cash Flow	4.36M	3.94M	148.90K	6.72M	50.34M	12.95M

Axe Compute Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.20
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AGPU, the sentiment is Positive. The current price of 7.2 is above the 20-day moving average (MA) of 6.47, above the 50-day MA of 6.34, and below the 200-day MA of 12.07, indicating a neutral trend. The MACD of 0.11 indicates Negative momentum. The RSI at 54.35 is Neutral, neither overbought nor oversold. The STOCH value of 36.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AGPU.

Axe Compute Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EKSO	53 Neutral	$26.90M	-1.58	-85.01%	―	-16.59%	43.20%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FEMY	45 Neutral	$35.36M	-0.82	-376.23%	―	63.53%	12.49%
AGPU	42 Neutral	$23.16M	-0.06	―	―	-47.20%	-163.70%
GCTK	42 Neutral	$3.42M	>-0.01	―	―	―	60.83%
WOK	41 Neutral	$186.44K	―	―	―	―	―